P rostate cancer is the most common solid cancer in men (diagnosed in 12%) and is often fatal (9% of male cancer deaths). It is difficult to manage clinically due to a poor current understanding of what dictates its highly variable natural history and of what underlies the development of castration-resistant disease 1 . Extensive data on the structure of prostate cancer genomes have been published [2] [3] [4] [5] [6] , including work from our own consortium [7] [8] [9] [10] . These studies have identified a number of genetically distinct subgroups, including cancers with ERG, ETV1, ETV4, FLI1, SPOP, FOXA1 and IDH1 alterations. Overlapping with these categories, cancers may have alterations in PI3K and DNA repair pathways, with the latter significantly over-represented in advanced disease 4 . However, we have relatively limited understanding of the ordering of genetic events, with the exception that ETS gene alteration appears to represent an early event while mutations of AR are later, sometimes convergent events occurring in advanced and metastatic disease. Indeed, we have very little understanding of the evolution of mutational processes, the various genetic paths that cancers traverse on their way to progression, the levels of heterogeneity at different stages of development, or the effect of these factors on clinical outcome.
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Gene status has been used in studies designed to improve the poor predictive value of conventional clinical markers (PSA, , amplification of AURKA together with the MYCN gene 13 , and coordinated loss of MAP3K7 and CHD1 14 have been reported to have prognostic value. A number of commercial prognostic tests based on gene expression profiles are also available [15] [16] [17] , and a classification framework has been proposed 18 . Improvements in the treatment of castration-resistant disease have been made through better targeting of AR regulation using abiraterone 19 and enzalutamide 20 , while PARP inhibitors are effective against cancers harboring BRCA1 or BRCA2 mutations and other defects in DNA repair pathways 21 . However, notable advances have been made recently through the retasking of approved drugs 22 . In this study, we use previously unpublished whole-genome DNA sequencing data in combination with published data to provide insights into the mechanism of progression of prostate cancer to lethal disease and to design new molecularly based strategies for drug targeting.
Results
We whole genome sequenced cancerous and matched normal samples from 87 primary prostate cancers from the UK and 5 from China, together with 10 hormone-naive prostate metastases and 10 castration-resistant metastases from the USA. Our analysis (see Methods) yields insights into the nature and order of acquisition of driver alterations, genomic heterogeneity in primary and metastatic cancers, changes in mutational signatures during progression and potential drug targets. In addition, we identify coding and noncoding drivers by combining single nucleotide variants (SNVs) and small insertions/deletions (indels) in our dataset with those from
The Cancer Genome Atlas (TCGA) 4 (425 samples), the COSMIC database 23 (243 samples) and Stand Up to Cancer 24 (SU2C-PCF, 150 samples) to give a combined dataset, hereafter referred to as the 'joint dataset' , comprising 710 primary cancers and 220 metastases. Supplementary Table 1 summarizes the genes affected in both our study and the joint dataset.
For the 112 cancer-normal pairs in our cohort, we identified 392,753 SNVs, 54,952 indels and 10,921 chromosomal rearrangements (Fig. 1) . The mean genome-wide substitution rate was 1.23/Mb, with a significant difference in mutational burden between the primary (0.99) and metastatic (2.30) samples (P = 4.4 × 10 −15 , Methods). Moreover, within the metastatic subset, mutation burden was higher in men treated with androgen deprivation therapy (ADT, also referred to as castration resistant prostate cancer, CRPC) than treatment-naive men (2.98 vs. 1.61, P = 0.015). There were also significantly more rearrangements in metastatic than in primary samples (P = 0.0059), while the proportion of breakpoints attributed to a chromoplexy-like event 25 was indistinguishable between the two groups. Within the metastatic group, the ADT samples had more rearrangements than did the hormone-naive (P = 0.027), with no difference in the proportion of chromoplexy-like events (Fig. 1) .
Genes of interest were determined through a comprehensive set of analyses to identify excess non-synonymous mutations in coding regions; excess missense mutations within a gene, indicative of an oncogenic driver; excess mutations in noncoding regions; regions with an excess of structural variants in either ETS + or ETS -cancers; and regions with recurrent copy number aberrations (CNAs) in either ETS + or ETS -cancers. Overall, we identified 73 genes with evidence for involvement in prostate cancer ; number of SNVs identified in each sample; proportion of small indels associated with microhomology or repetitive regions; number of insertions, deletions and complex indels in each sample; and total number of structural variants in each sample, separated into inversions, translocations, deletions and tandem duplications. Sample ordering is reported in Supplementary Table 7. development (Fig. 2 , Table 1 and Supplementary Table 2 ). Based on a literature search, each gene was assigned a high, medium or low level of previous supporting evidence (Table 1 and Supplementary  Table 2 ). In addition to 22 genes with little or no previous evidence of involvement in prostate cancer (Table 1 , low previous evidence), we provide corroborating evidence for 8 more genes previously lacking strong evidence of driving prostate cancer (Table 1 , medium previous evidence).
Coding driver mutations. We identified 28 genes with an excess of non-synonymous coding mutations, 5 of which are previously unknown drivers in prostate cancer (Supplementary Table 2 ). TBL1XR1 was enriched in truncating SNVs and indels and is also located in a genomic region enriched for rearrangements in ETS + cancers (chr3:172-179Mb) (Fig. 3) . These rearrangements result in loss of heterozygosity (LOH) or, in one case, homozygous deletion, suggesting a cancer suppressor role for this gene. Another significantly mutated gene primarily affected by truncating mutations was ZMYM3, which encodes a component of CoREST, a transcriptional repressor complex including REST (RE-1 silencing transcription factor) and involved in suppression of neuronal differentiationrelated genes in non-nervous tissues 26 . In addition, two further CRPC samples from the SU2C-PCF study 24 had nonsense mutations and one sample in our study had a 70-kb exonic deletion in REST.
Two other genes with recurrent truncating mutations were IL6ST and CASZ1 (Fig. 3) . The latter is a putative cancer suppressor in neuroblastoma 27 , while the former encodes glycoprotein 130, the signal-transducing subunit of the interleukin 6 (IL6) receptor.
The pattern of mutations we observe in the joint dataset for IL6ST is dominated by truncating events. Moreover, this gene is located in a genomic region recurrently rearranged in ETS + cancers, resulting in either LOH or homozygous deletion (four cases of each), suggesting a cancer-suppressive role. TBX3, previously reported to harbor mutations in breast cancer 28 , exhibited a mixed pattern of mutations with mostly missense mutations and two cancers harboring truncating events.
Analysis of missense mutations identified recurrent mutations in seven more genes, of which two are newly reported (Supplementary  Table 2 ). CNOT3 exhibited mutation hotspots altering two amino acid positions, Glu20Lys (4 of 932 samples) and Glu70Lys (5 of 932 samples), as well as a nonsense mutation in a single sample (Fig. 3) . CNOT3 has a known cancer-suppressive function in T-cell acute lymphoblastic leukemia 29 . Enrichment for missense mutations was identified in RPL11, which encodes a ribosomal protein and putative cancer suppressor upstream of the MDM2-TP53 pathway 30 . In contrast to findings of previous studies, the enrichment for missense mutations in both CNOT3 and RPL11 suggests oncogenic, rather than tumor suppressor, roles in prostate cancer. A comparison between coding mutations in metastatic and primary samples in the joint dataset identified enrichment in metastases for mutations in TP53, AR, KMT2C, KMT2D, RB1, APC, BRCA2, CDK12, ZFHX3, CTNNB1 and PIK3CB (Supplementary Table 2 ), confirming previous studies 3, 24 .
Noncoding driver mutations. Analysis of noncoding portions of the genome identified two regions significantly enriched for TBL1XR1  ZFHX3  NCOA7  ZBTB16  ASH1L  GPATCH8  APC  AR  UBTF  IL6ST  ADAM28  PPP2R2A  MYST3  PPAP2A  ETV3  SPOP  MLL3  ROBO1  ROBO2  ZNF292  PDE4D  NEAT1  CDKN1B  CHD1  FOXA1  TP53 , n = 53 ETS biologically independent samples); bottom, genes enriched in metastatic (met) samples (Fisher's exact test, n = 20 metastatic, n = 98 primary biologically independent samples). Right, the fraction of samples bearing each type of aberration. DDR, DNA damage response; 'hemi. loss', loss of heterozygosity resulting from CNA; 'homo. loss', homozygous deletion resulting from CNA; 'two allele loss + sub/indel', genes in triploid regions bearing aberrations of all three gene copies. Sample ordering is reported in Supplementary Table 7. mutations. NEAT1, which produces a long noncoding RNA recently reported to be associated with prostate cancer progression 31 , was mutated in 13 of 112 ICGC samples, with significant over-representation in patients with metastatic disease (6 of 20 metastases vs. 7 of 91 primaries, Fisher's exact test, P = 0.012; Fig. 3) . Out of the metastatic tumors, NEAT1 mutations were found only in patients who had undergone ADT, consistent with the link between high NEAT1 expression and resistance to AR-targeting therapies 31 . Notably, two of these six samples had two separate NEAT1 mutations. The FOXA1 promoter also had significant evidence of selection. This gene modulates AR-regulated transcriptional signaling 32 and has previously been found to harbor recurrent coding mutations 5 . In our series, we identified 14 samples with coding and 6 samples with noncoding mutations, with two samples (PD14721a and PD12813a) bearing both a coding and a noncoding mutation. We also identified mutations in the promoter for FOXP1, a gene with known cancer-suppressive effect in prostate tumorigenesis 33 , in three samples, but this was insufficient to reach statistical significance.
Structural variant enrichment in ETS
+ and ETS -cancers. The density of rearrangements varies across the genome as a result of various factors, including chromatin state, GC content, gene density, replication timing and repetitive sequence. To remove the effect of these factors, we segmented interbreakpoint distance across the genome separately in ETS + and ETS -cancers and identified regions with differential enrichment for rearrangements between the two Genes were identified in our study using several methods, detailed in the last column: dN/dS; enrichment for SVs or CNAs in ETS + or ETS -cancers; enrichment for truncating mutations or homozygous deletions; clinical correlation. From a PubMed literature search, prior evidence for each gene being a driver of prostate cancer was classified as 'low' if the gene has not been previously reported as playing a role in prostate cancer tumorigenesis or progression. Isolated alterations may have been observed or biological evidence for importance may have been presented as indicated in the prior evidence column. Prior evidence was classified as 'medium' for genes reported previously as playing a role in prostate carcinogenesis or progression but currently lacking statistical support based on genetic alterations. Evidence considered included presence of multiple genetic alterations, SNP associations, and known cancer genes in other tissues. The high confidence genes are those that are widely accepted to represent cancer genes and to be altered in prostate cancer, including genes such as HRAS, SPOP and IDH1. In each case, there are two or more of the following: statistical verification of higher incidence, biological experiments, clinical correlations, confirmation in multiple studies, recognition as cancer genes in other cancer types. dN/dS, non-synonymous:synonymous ratio calculated for all SNVs and indels; dN/dS (missense), non-synonymous:synonymous ratio calculated for missense SNVs only; SV, structural variant; CNA, copy number aberration; SNV, single nucleotide variant; indel, small insertion/deletion; ETS, E26 transformation-specific.
subtypes. The functional importance of many of these regions was supported by an excess of truncating mutations or CNAs. In addition to regions previously identified as enriched for rearrangements in ETS + cancers (FOXP1, RYBP, SHQ1, PTEN and TP53) [34] [35] [36] [37] , we identified two unreported regions. The region chr5:55-59Mb covers the genes PPAP2A, PDE4D, MAP3K1 and IL6ST (Fig. 3) . In IL6ST, we also detected significant enrichment for coding mutations, suggesting this is the main target of the aberrations. At chr3:171-178Mb, TBL1XR1 was similarly enriched for both rearrangements and truncating mutations.
In ETS -cancers, we confirmed a previously reported enrichment for rearrangements containing CHD1 38, 39 . A target of enriched rearrangements in the region chr1:149-158Mb is likely ETV3. In 5 of 9 cancers, ETV3 was exclusively affected by these events (4 LOH by deletion and 1 by translocation). Additionally, 1 cancer had a truncating mutation (Arg413fs*3) and 2 had missense mutations (Ala73Val and Leu37Gln). In total, 12 patients had localized alteration, 10 of whom had ETS -cancers. Moreover, in the joint dataset, there were four cancer samples with truncating mutations in this gene. In contrast to ETV4, the nature of variants in ETV3 is indicative of a tumor-suppressive role in prostate cancer. Manual inspection of the recurrently rearranged region chr3:76-84Mb identified ROBO1 and ROBO2 as possible targets (Fig. 3 ). In total, 16 of 112 samples had an event affecting one or other of these genes, and in 4 samples both were affected. Previously implicated in pancreatic ductal adenocarcinoma 40 , these two genes have not been previously reported in the context of prostate cancer.
Events enriched at chr6:80-114Mb indicate that ZNF292 is a possible target. Eleven of 112 patients (5 ETS + and 6 ETS -) had loss of at least one chromosome copy, and in 2 patients there was a homozygous loss specifically targeting ZNF292. Moreover, the joint dataset contained 5 of 932 samples with a truncating mutation, further suggesting a cancer-suppressive function for this gene in prostate cancer. Another gene affected by recurrent rearrangements on 6q was SENP6, which encodes a small ubiquitin-like modifier (SUMO)-specific protease that removes SUMO polypeptides from conjugated proteins 41 and may influence AR function 42 . Of note, 4 of 5 rearrangements in this region affected SENP6 only, leading to a significant reduction in expression; P < 0.0001 ( Supplementary  Fig. 1 ). Finally, located at chr6:126Mb, the nuclear receptor coactivator NCOA7 was altered in 6 samples, with 1 sample having homozygous loss.
Further regions enriched for rearrangements in ETS -cancers were chr2:133-144Mb (LRP1B), chr8:112-114Mb (CSMD3) and chr8:40-41Mb (MYST3). The first two genes are very large and fall within reported fragile sites 43 . Nevertheless, preferential enrichment of breakpoints in ETS -cancers may suggest either that underlying structure, such as AR binding sites or nucleosome structure, or that epistatic interactions between ETS fusion and other rearrangements affect the occurrence of rearrangements at these loci. Samples containing structural variants affecting MYST3 were found to have significantly reduced RNA expression; P = 0.025 ( Supplementary  Fig. 1 ).
Timing of copy number aberrations. To identify routes to progression in prostate cancer, we developed an approach by which to order the occurrence of CNAs by combining information on the clonality of CNAs, timing relative to whole-genome duplication (WGD), and timing of homozygous deletions relative to neighboring hemizygous losses. Information from all tumors was combined using a Bradley-Terry model to give the most likely ordering of events. By applying a set of logical rules (see Methods), we deciphered the temporal ordering of subclonal CNAs within each cancer. In general, homozygous deletions appeared late in oncogenesis, corroborating previous findings that homozygous deletions are associated with advanced disease [44] [45] [46] . Clear differences emerged in the evolution of ETS + and ETS -prostate cancers. Where present, the deletion between the TMPRSS2 and ERG genes in ETS + cancers was an early (generally clonal) event, as was gain of chr8q in the locus 112-137Mb (Fig. 4a) chr13:32-91Mb (which includes BRCA2, RB1 and FOXO1) and chr6:73-120Mb are followed by losses at chr2:124-142Mb, then by gains at chr3:100-187Mb, and then whole chromosome gain of chr7 (Fig. 4b) . Loss of CHD1 has been previously implicated in the initiation of ETS -prostate cancers, preventing ERG rearrangement in the prostate 38 , and our data confirm the exclusivity between ETS positivity and homozygous loss of CHD1 (Fig. 4c) . In both ETS + and ETS -cancers, WGD correlated with loss of chromosomal segments at chr1:94Mb, chr2:140Mb, chr12:12Mb, chr16:85Mb and chr17:7Mb (Fig. 4c) . From timing analysis, these losses appear to occur synchronously with WGD in most cases. Gains at chr8:101Mb occurred before WGD, gains at chr3:131Mb occurred synchronously, and gains at chr7:88Mb tended to follow WGD.
Timing of point mutations and indels. SNVs and indels were clustered according to their cancer cell fraction using a Bayesian Dirichlet process 47 . The proportion of SNVs identified as subclonal showed considerable variation across cancers, but was significantly higher in primary than metastatic samples (P = 0.022, Wilcoxon rank sum test, Fig. 5a ), as was the proportion of subclonal indels (P = 0.00033) and the fraction of the genome with subclonal CNAs (P = 0.0037, Supplementary Fig. 2 ). This is apparent evidence for a bottleneck in acquiring metastatic potential rather than a response to treatment, since levels of heterogeneity in untreated metastases are no lower than in androgen-deprived metastases (Fig. 5a) .
The levels of heterogeneity observed in SNVs and indels were correlated (Pearson r = 0.57, P = 2.3 × 10 −9
, Fig. 5a ). Higher levels of heterogeneity were observed among indels than SNVs (P = 2.4 × 10 −8 ). However, the possibility cannot be ruled out that variant calling of indels may have greater sensitivity for low-allele-frequency variants than calling of SNVs.
Driver SNVs were identified as clonal or subclonal in each sample according to the cluster to which they were assigned, with 84 classified as clonal and 22 (21%) as subclonal. Our power to detect subclonal mutations is limited by sequencing depth, and the real number of subclonal driver mutations is likely much higher. The driver mutations identified as subclonal included 2 mutations in APC in the same sample, PD14713a. Notably, this cancer has undergone clonal loss of one copy of chr5q, followed by mutations in APC in two different subclones ( Fig. 5b and Supplementary Fig. 3 ), suggesting convergent evolution. Five other samples each had two subclonal drivers: PD12808a has a missense mutation in ZNF292 and an essential splice site mutation in SMAD2; PD13401a has a nonsense mutation in PPP1R3A and a mutation in the promoter of NEAT1; PD13402a has a nonsense mutation in USP34 and an essential splice site mutation in ABI3BP (Fig. 5b) ; PD12820a has a missense mutation in USP48 and an essential splice site mutation in ASXL2; and PD13389a has a frameshift mutation in PHF12 and an essential splice site mutation in TBX3 (not shown). Subclonal mutations were also seen in several common drivers, including 1 in TP53 (PD13339a) and 1 in PTEN (PD12840a). By contrast, SPOP was mutated in 10 samples, always clonally and always in ETS -tumors (Fig. 2) .
Mutational signatures. Analysis of the mutational signatures by non-negative matrix factorization (NMF) showed that, in addition to the ubiquitous 'clock-like' signatures 1 and 5, there was presence of the previously described 48 signatures 2, 3, 8, 13 and 18. Signature-3-positive samples were enriched for germline or somatic mutations in BRCA1 and BRCA2 genes (4 of 6 samples), as reported previously 48 (Fig. 1) . However, the presence of high levels of microhomology-mediated deletions was even more strongly correlated with the presence of BRCA mutations (6 of 6 samples). Separating the mutations into early clonal, late clonal and subclonal epochs (see Methods) showed that the proportion of signature 1 mutations decreases over time, suggesting an increase of cancer-associated mutagenic processes relative to innate processes (P = 2.2 × 10 ). In a recent report of 560 breast cancer whole genomes, signature 8 correlated with DNA damage repair deficiency 50 . Androgen signaling is known to positively regulate multiple genes involved in DNA repair 51, 52 , while androgen deprivation impairs DNA double-strand break repair 53 . In support of these previous reports, the proportion of mutations assigned to signature 8 is consistently higher among later appearing (subclonal) populations of cells (55% ± 24%) than earlier (clonal) populations (28% ± 12%) (t-test,
, Supplementary Table 3 ). The proportion of metastases with evidence for the action of signature 8 was higher than that for primary tumors, although not reaching statistical significance (8 of 20 metastases vs. 25 of 92 primaries, Fisher's exact test P = 0.28). Increased prevalence of DNA-damage related genes in metastatic prostate cancer, as well as the observations made in this study, warrant an extensive study of mutational signatures in therapy-naive disease and CRPC in a larger dataset to explore the relevance of checkpoint inhibition as an alternative therapy for advanced prostate cancer.
Clinical correlates. CDH12 and ANTXR2 alterations were significantly associated with time to biochemical recurrence (BenjaminiHochberg adjusted P = 0.0060 (CDH12) and 0.012 (ANTXR2), HR (hazard ratio) = 9.3 and 7.7, Cox regression model, Fig. 6 ) and were PD14713a PD12840a PD13401a PD13399a
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NEAT1 T1 T1 1 1 1 1 1 1 1 1 1 1 P P P P P P P ABI3BP P P P P P P P P 4 USP34 34 34 significant predictors of biochemical recurrence independent of cofactors Gleason, PSA at prostatectomy, and pathological T-stage (P = 0.00061 (CDH12) and 0.0015 (ANTXR2), HR = 7.3 and 6.5, respectively; Cox regression model, Supplementary Table 4) . A Cox regression model containing a combination of CDH12, ANTXR2, SPOP, IL6ST, DLC1 and MTUS1 mutations was determined to be an optimal predictor of time to biochemical recurrence and was a significant improvement over a baseline model of Gleason, PSA at prostatectomy, and pathological T-stage (model χ 2 test, P = 0.00053). The number of mutational signatures identified in a cancer was negatively correlated with time to biochemical recurrence in prostatectomy patients (P = 0.014, HR = 3.0; Cox proportional hazards model on number of processes greater than 3, Supplementary  Fig. 4 ) and was an independent predictor (P = 0.0061, HR = 3.6; Cox proportional hazards model). The number of SNVs detected was also an independent prognostic biomarker (P = 0.031, HR = 1.005; Cox proportional hazards model). The numbers of both samples and events in this study are modest, and further analysis of larger cohorts is required to establish firmly these findings.
Druggable targets in the prostate cancer disease network.
A key opportunity arising from systematic analyses of cancer genomics is the early identification of therapeutic intervention strategies. To this end, we applied established chemogenomic technologies using the canSAR knowledge base 54 to map and pharmacologically annotate the cellular network of the prostate disease genes identified in this study. We derived the network using curated protein-protein and transcriptional interaction data. We included the protein products of the genes identified in this study and other key proteins that directly interact with these proteins or affect their function (see Methods and Supplementary Fig. 5 ). This resulted in a focused prostate network of 156 proteins. Each protein was annotated according to multiple assessments of 'druggability'; i.e., the likelihood of the protein being amenable to small molecule drug intervention (Table 2  and Supplementary Table 5 ). We found that prostate cancer driver genes were embedded in a highly druggable cellular network that contains 11 targets of approved therapies and 7 targets of investigational drugs. As well as the AR and the glucocorticoid receptor (GR), the network contains targets of drugs approved for other indications, several of which (for example, BRAF, ESR1, RARA, RXRA, HDAC3) are under clinical investigation for prostate cancer.
Seven proteins in the prostate network are targets of drugs now in clinical trials. In particular, the ataxia-telangiectasia mutated (ATM) inhibitor AZD-0156, currently in phase 1 for safety assessment, is a likely candidate for exploration in prostate cancer owing to the recently described role of DNA damage repair, particularly in advanced prostate cancers 21, 55 . The network highlights targets of phosphatidylinositol-3-OH kinase pathway inhibitors (PI3K, AKT1) that are undergoing clinical investigation in prostate cancer, as well as IDH1 and MDM2 drug targets.
To give an indication of the potential of these drugs, we analyzed the most recent drug sensitivity data (GDSC 56 , see URLs). Eighteen drugs acting on our network were tested in GDSC on prostate cancer cell lines. Of these, 5 showed significant effect on growth inhibition and the remaining 13 drugs showed weak activity in at least one cell line (Supplementary Table 6 ). However, to validate fully the potential of these drugs, extensive drug sensitivity testing needs to be performed in disease-relevant cancer models that correctly reflect the patient population.
Potential future opportunities for prostate cancer therapy are also highlighted by 13 proteins that are under active chemical biology or drug discovery investigation ( A further 49 proteins are predicted to be druggable and therefore potentially amenable to drug discovery. These include the known prostate cancer protein SPOP, the transcription activator BRG1 (SMARCA4), CDK12 and the CREB binding protein CREBBP.
In summary, we find that 80 of the 156 proteins central to the prostate disease network are either targets of existing drugs or have the potential to be targeted in the future. To maintain an up-to-date view of this analysis, we provide a link to a live page in canSAR (see URLs).
Discussion
The analysis of whole-genome sequence data from 112 prostate cancers has highlighted many of the genetic factors underlying the processes of carcinogenesis, progression, metastasis and the acquisition of drug resistance. Supporting evidence has been provided for 30 candidate driver genes with limited or no previous support, including the noncoding drivers NEAT1 and FOXA1. Proteins in bold typeface are derived from genes identified as prostate drivers in this study or proteins that have a significant known interaction with these proteins.
Through the timing of genomic aberrations, we have a picture of the possible routes to progression in prostate cancer. Most driver mutations may occur either clonally or subclonally, but mutations in SPOP and ETS fusions occur early in cancer development and are exclusively clonal. Whereas the gain of 8q and ETS fusion appear to be sufficient to drive a dominant clonal expansion, ETS -cancers typically need a combination of large-scale losses, acquired over an extended period of time. Known cancer drivers are frequently observed subclonally, and two competing drivers are seen in several cancers. Metastases have less genomic heterogeneity, likely resulting from a bottleneck in achieving metastatic potential.
We observe changes in the mutational processes operative upon cancers during progression. Signature 8 was enriched in subclonal expansions, and signatures 13 and 18 were enriched in metastatic cancers. Cancers with germline or somatic BRCA1 or BRCA2 mutations were enriched for signature 3, demonstrating the effect of double-strand repair defects throughout cancer evolution.
Losses of CDH12 and ANTXR2 result in poorer recurrence-free survival. We identify 69 prostate cancer-associated proteins that are either targets for existing drugs or new potential targets for therapeutic development.
Analysis of the whole-genome sequences of over 100 prostate cancers has started to reveal the complex evolutionary pathways of these cancers. The early acquisition of driver aberrations, including ETS fusions and whole genome duplications, strongly affects the acquisition of subsequent aberrations. Acquisition of individual mutations affects both the subsequent likelihood of metastasis and response to treatment. Network analyses identified, in addition to previously known drivers, targets that could be exploited for clinical investigation with existing drugs as well as targets for new drug discovery, giving potential for the results of genome analysis to be translated rapidly into therapeutic innovation and patient benefit.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0086-z. 69 , an integrated clinical-molecular autopsy study of metastatic prostate cancer, were subjects in the current study. Subjects consented to participate in the Johns Hopkins Medicine IRB-approved study between 1995 and 2005 (Supplementary Table 7) . Subject A17 had a germline BRCA1 mutation, as previously reported 70 .
Norwich Medical School, University
DNA preparation and DNA sequencing. DNA from whole blood samples and frozen tissue was extracted and quantified using a dsDNA assay (UK-Quant-iT PicoGreen dsDNA Assay Kit for DNA) following the manufacturer's instructions with a fluorescence microplate reader (Biotek SynergyHT, Biotek). Acceptable DNA had a concentration of at least 50 ng/μ l in TE (10 mM Tris, 1 mM EDTA) and an OD 260/280 between 1.8 and 2.0. WGS was performed at Illumina, Inc. (Illumina Sequencing Facility, San Diego, CA, USA) or the BGI (Beijing Genome Institute, Hong Kong), as described previously, to a target depth of 50× for the cancer samples and 30× for matched controls 8 . The Burrows-Wheeler Aligner was used to align the sequencing data to the GRCh37 reference human genome 71 .
Variant calling pipeline. SNVs, insertions and deletions were detected using the Cancer Genome Project Wellcome Trust Sanger Institute pipeline as described previously 8 . In brief, SNVs were detected using CaVEMan with a cut-off 'somatic' probability of 95%. Postprocessing filters were applied. Insertions and deletions were called using a modified version of Pindel 72 . Variant allele frequencies of all indels were corrected by local realignment of unmapped reads against the mutant sequence. Structural variants were detected using Brass 8 . A positive ETS status was assigned if a breakpoint between ERG, ETV1 or ETV4 and previously reported partner DNA sequences was detected.
Mutation burdens. Mutation burdens were compared between primary and metastatic samples and between ADT and hormone-naive samples using a negative binomial generalized linear model (GLM), implemented with the R package MASS. Sample type was found to be an independent predictor of number of SNVs, as was age at time of sampling.
Timing of copy number events. We developed an approach to order the occurrence of CNAs by combining three sources of information: (i) clonality of CNAs; (ii) timing relative to whole-genome duplication, and; (iii) timing of homozygous deletions relative to neighboring hemizygous losses. Information from all tumors was combined using a Bradley-Terry model to give the most likely ordering of events during progression of prostate cancer.
The Battenberg algorithm was used to detect clonal and subclonal somatic CNAs and to estimate ploidy and cancer content from the next-generation sequencing data as previously described 73 . Briefly, germline heterozygous SNPs were phased using IMPUTE2 and a-and b-alleles were assigned. Data were segmented using piecewise constant fitting 74 and subclonal copy-number segments were identified via a t-test as those with b-allele frequencies that differed significantly from the values expected of a clonal copy number state. Ploidy and cancer purity were estimated with the same method used by ASCAT 75 .
In this cohort, we defined WGD samples as those that had an average ploidy greater than 3. For tumors that had not undergone WGD, gains were defined as those regions that had at least one allele with copy number greater than 1, while losses were defined as those segments that undergone LOH. For tumors that had undergone WGD, losses were called in those segments with at least one allele with copy number of less than 2, whereas gains were called for those with an allelic copy number greater than 2. An extension of this logic was used for subclonal copy number segments; the evolving cellular fraction was always defined as that which deviated away from overall ploidy (defined as 2 for non-WGD samples and 4 for WGD samples). For example, if 75% of cells in a non-WGD tumor have a copy number of 3 + 1 at a given genomic loci, with the remaining 25% of cells having a copy number of 2 + 1, then we assume there has been clonal gain to 2 + 1 and then a subclone containing 75% of cells has undergone a further gain.
Three independent approaches were used to extract evolutionary data from each cancer sample. The first involved ordering clustered subclonal cancer fractions, the second used implicit ordering of clonal homozygous deletions in relation to losses, and the third estimated the relative timing of whole genome duplication. The logical arguments used in each approach are considered in turn. First, Battenberg algorithm-derived estimates for the cellular fraction and s.d. of each subclonal aberration were input to a Markov chain Monte Carlo hierarchical Bayesian Dirichlet process to group linked events together in an unsupervised manner. This defined clusters of different cell populations, each present at a calculated cancer cell fraction. The pigeonhole principle was then used to determine the hierarchical relationship between these clusters. Using this process, gains, losses and homozygous deletions were ordered with the following caveat to ensure that only independent events are ordered: if there was a clonal and subclonal gain (or loss) at the same locus, then only the clonal or initial gain (or loss) was ordered. Second, homozygous deletions have implicitly occurred after loss of heterozygosity at the same locus. Finally, the parsimony principle was used to define the allele counts that correspond to early and late changes in relation to WGD. For losses, if the minor allele copy number equals 0, then the loss occurred before WGD. Otherwise the loss occurred after WGD. Regarding gains, if the major allele copy number is twice or greater than ploidy, then the gain occurred before WGD. Otherwise, the gain occurred after WGD.
The above arguments allow us to gain insights into the order of copy number events in each individual tumor sample. To establish a consensus order across a cohort of tumor samples requires the ordering data to be integrated across all samples. As specific copy number events (location of breakpoints and the individual copy number states) tend to be unique to individual samples, we defined reference copy number segments that occurred recurrently. These were then used to build an overall contingency table.
The reference genomic segments were defined as regions that were recurrently aberrant. Regions of significant recurrence (false detection rate (FDR), P < 0.05) were determined by performing 100,000 simulations, placing the CNAs detected from each sample in random locations within the genome. The process was repeated for gains, LOH and homozygous deletions and the randomly generated copy number landscape compared to that arising from this cohort provided significance levels. Each significantly aberrant region was initially segmented using all breakpoints from all the events that contributed to that region. For instance, the significantly enriched region for LOH:chr8:0-44Mb contains over 300 breakpoints drawn from all the samples that contain LOH at chromosome 8p. We computed significantly recurrent regions and reference segments for both ETS + and ETS -sample subgroups.
Performing pair-wise comparisons between all segmented results using the Bradley-Terry method described below proved computationally expensive, and therefore the total number of segments used in the pairwise comparison was rationalized by grouping reference segments to make combined segments of minimum length 1 Mb.
We then considered each tumor sample in turn. If any copy number event overlapped the reference genomic segments and was ordered in relation to any other event (that also overlapped regions of significance), those overlapped reference segments were ordered in comparison to other overlapped reference segments. In addition to these reference segments, the TMPRSS2-ERG deletion was ordered more stringently by considering only those segments that could result in the gene fusion, and not merely overlap the locus. In this manner, a contingency table of contests was constructed using reference genomic segments as the variables. We built contingency tables for both ETS + and ETS -tumor samples to determine whether their evolutionary trajectory differed significantly.
An implementation of the Bradley-Terry model of pairwise comparison in R 76 with bias reduced maximum likelihood estimated the ability or overall order of each individual reference segment.
Subclonal analysis. The fraction of each cancer genome with subclonal CNAs was calculated as the total amount of the genome with subclonal CNA, as identified by the Battenberg algorithm, divided by the total amount of the genome that had CNAs. One sample (PD13397a, Supplementary Table 8 ) was identified as having very low cellularity, as it had a completely flat copy number profile and only 411 identified SNVs. Since CNAs could not called in this sample, it was not possible to adjust allele frequencies to cancer cell fractions (CCFs), and this sample was excluded from subclonality analysis. SNVs and indels were separately clustered using a Bayesian Dirichlet process, as previously described 47 . Clonal variants are expected to cluster at a CCF close to 1.0. However, in 18 tumors (Supplementary  Table 8 ), there was no cluster in the range 0.95-1.05. The likely cause of a shift in CCF is inaccuracy in copy number calling, and these samples therefore failed quality control and were excluded from subclonality analysis. From Markov chain Monte Carlo sampling carried out in the Dirichlet process model, the posterior probability of each variant having a CCF below 0.95 was estimated. Variants with a probability above 80% were designated as 'subclonal' , those with probability below 20% were designated 'clonal' , and those with intermediate probabilities were designated as 'uncertain' . The fraction of subclonal variants used in Fig. 5 and Supplementary Fig. 2 was then calculated after excluding uncertain variants.
Mutational spectra. The mutational spectra, defined by the triplets of nucleotides around each mutation of each sample, were deconvoluted into mutational processes as previously described 48, 77 . Clonal and subclonal variants were separated as defined above. Further separation of clonal mutations was performed for mutations in genomic regions that had undergone copy number gains. These mutations were classified as 'early' or 'late' depending whether their observed allele frequencies were more likely to indicate their presence on 2 or 1 chromosome copies, respectively, as assessed by binomial probability. Assignment of mutations to mutational signatures was carried out on each subset of mutations (early, late, clonal, subclonal), as well as on all mutations from each sample (Supplementary Table 3 should be sufficient to detect 90% of driver genes with prevalence 2% with 90% power, given the average mutation rate within our samples.
Data exclusions
Describe any data exclusions. Samples were excluded from the subclonal analysis if they had a poor copy number profile.
Replication
Describe whether the experimental findings were reliably reproduced. No experiments were used within this study
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Not applicable
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Not applicable. All samples were run through common analysis pipelines.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size ( ) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons 
